^
    4d
    Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined with Radiotherapy. The XXX Study. (PubMed, Int J Radiat Oncol Biol Phys)
    XXX is the largest study that confirms the feasibility and promising efficacy of concurrent treatment, pending confirmation in prospective trials.
    Clinical • Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    5d
    STATEsMAN- A Phase 2 trial of SaciTuzumAb TirumotEcan (sac-TMT) in patients with MetastAtic castration resistant prostate cancer (mCRPC) (ACTRN12625001382460)
    P2, N=40, Not yet recruiting, Metro South Hospital and Health Services
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    6d
    Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor Cells. (PubMed, Anal Chem)
    Triple-negative breast cancer (TNBC) patients undergoing sacituzumab govitecan (SG) therapy suggests CTCs can be successfully detected...With the unique advantages of cell viability preservation, 100% diagnostic specificity, modular design adaptability, and cost-effectiveness, the PM-PAM platform establishes a new paradigm for liquid biopsy applications. This technology also shows the particular promise for monitoring antibody-drug conjugate (ADC) treatment efficacy through dynamic Trop-2 expression analysis in breast cancer management.
    Journal • Circulating tumor cells
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    6d
    Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation. (PubMed, Front Immunol)
    Therapies targeting DNA repair pathways, angiogenesis, and androgen receptor signaling-particularly via PARP inhibitors and antibody-drug conjugates like sacituzumab govitecan-have demonstrated clinical benefit...This review delineates recent developments in targeted and immunotherapeutic strategies, emphasizing the role of TILs in shaping treatment response and highlighting combinatorial approaches that synergize molecular targeting with immunomodulation. Through a comprehensive understanding of TNBC's molecular and immune landscape, we propose new therapeutic trajectories to improve clinical outcomes in this challenging malignancy.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • mTOR (Mechanistic target of rapamycin kinase) • PI3K (Phosphoinositide 3-kinases)
    |
    HER-2 amplification
    |
    Trodelvy (sacituzumab govitecan-hziy)
    9d
    OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    9d
    TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, First Hospital of China Medical University
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • Trodelvy (sacituzumab govitecan-hziy)
    9d
    Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study. (PubMed, Breast Cancer Res Treat)
    This first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1-positive disease.
    Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    12d
    Interrogating the Involvement of Autophagy, Senescence, and the Immune System in the Actions of Sacituzumab Govitecan as an Anticancer Agent. (PubMed, Front Biosci (Landmark Ed))
    While SG has shown significant clinical benefit, the objective response rate (ORR) observed with SG in pretreated mTNBC patients in the Phase I/II basket study was 33.3%, indicating a heterogeneous response profile to SG. This article explores the potential influence of autophagy, senescence, and the patient's immune system on the treatment response.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    13d
    WIN-B: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=76, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Trodelvy (sacituzumab govitecan-hziy) • Debio 0123
    13d
    A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)
    14d
    Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED (clinicaltrials.gov)
    P2, N=50, Completed, MedSIR | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide
    14d
    CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov)
    P1/2, N=46, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2026 --> Sep 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Trodelvy (sacituzumab govitecan-hziy)